Treatment options - Development of consensus guidelines

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue SUPPL. 1, 2005, Pages 25-33

  Lecha, M ^a   Effendy, I ^b   De Chauvin, M Feuilhade ^c   Di Chiacchio, N ^d   Baran, R ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b OWL University   (Germany)

^c SAINT LOUIS HOSPITAL   (France)

^d HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^e NAIL DISEASE CENTRE   (France)

Author keywords

Combination; Nail removal; Onychomycosis; Oral; Topical; Treatment

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CASPOFUNGIN; CICLOPIROX; ECHINOCANDIN; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; TIOCONAZOLE; VORICONAZOLE;

CANDIDA; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG TRANSPORT; FUNGICIDAL ACTIVITY; HEADACHE; HEALTH STATUS; HEMATOLOGIC DISEASE; HUMAN; INTERMETHOD COMPARISON; LIVER DISEASE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAIL INFECTION; NAUSEA; ONYCHOLYSIS; ONYCHOMYCOSIS; PRIORITY JOURNAL; REVIEW; SKIN TINGLING; TREATMENT INDICATION; TRICHOPHYTON MENTAGROPHYTES; URTICARIA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NAILS; ONYCHOMYCOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TINEA; TREATMENT OUTCOME; TRICHOPHYTON;

EID: 28444449468     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01284.x     Document Type: Review

References (40)

1. Joish VN, Armstrong EP. Which antifungal agent for onychomycosis? A pharmacoeconomic analysis. Pharmaco Economics 2001; 19: 983-1002.
2. Fouilloux B. Onychomycosis and quality of life. Ann Dermatol Venereol 2003; 130: 1275-1278.
3. Lecha M, Alsina M, Torres Rodriguez JM et al. An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 2002; 63: 366-379.
4. Tosti A, Hay R, Arenas-Guzman R. Patients at risk of onychomycosis - Risk factor identification and active prevention. J Eur Acad Dermatol Venereol 2005; 19 (Suppl. 1): 13-16.
5. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000a; 43: S57-S69.
6. Nishiyama Y, Asagi Y, Hiratani T et al. Morphological changes associated with growth inhibition of Trichophyton mentagrophytes by amorolfine. Clin Exp Dermatol 1992; 17: 13-17.
7. Muller J, Polak-Wyss A, Melchinger W. Influence of amorolfine on the morphology of Candida albicans and Trichophyton mentagrophytes. Clin Exp Dermatol 1992; 17: 18-25.
8. Bohn M, Kraemer KT. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc 2000; 90: 491-494.
9. Franz TJ. Absorption of amorolfine through human nail. Dermatology 1992; 184: 18-20.
10. Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101-103.
11. Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992; 17: 29-32.
12. Sidou F, Soto P. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers. Int J Tissue React 2004; 26: 17-24.
13. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111-115.
14. Halmy K. Experience with nail lacquers containing 5% amorolfine and 8% ciclopirox in patients with onychomycosis. Szemle 2003; 121-124.
15. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17: 61-70.
16. Marty JPL, Lambert J, Hamel L, Patouillard E. Treatment cost of three nail lacquers used in onychomycosis infection. Poster presented at the EADV 2003. Barcelona, Spain.
17. Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmoeconomics - An aid to better decision making. J Eur Acad Dermatol Venereol 2005; 19 (Suppl. 1): 34-39.
18. Gupta AK. Ciclopirox: an overview. Int J Dermatol 2001 ; 40: 305-310.
19. Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin 2003; 21: 469-479.
20. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551-1554.
21. Finlay AY, Lever L, Thomas R, Dykes PJ. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1:51-53.
22. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126: 28-32.
23. Haria M, Bryson HM, Goa KL, Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585-620. Review.
24. Erratum in: Drugs 1996; 52: 253.
25. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-429.
26. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol 2004; 140: 691-695.
27. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereal 2005; 19: 21-29.
28. Polak A. Combination of amorolfine with various antifungal drugs in dermatophytosis. Mycoses 1993; 36: 43-49.
29. Baran R, Feuilhade M, Combemale P et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-1183.
30. Erratum in: Br J Dermatol 2001; 144: 448.
31. Harman S, Ashbee HR, Evans EG. Testing of antifungal combinations against yeasts and dermatophytes. J Dermatolog Treat 2004; 15: 104-107.
32. Polak A. The past, present and future of antimycotic combination therapy.Mycoses 1999; 42: 355-370.
33. Correia O, Faergemann J, Nowicki R, Ro BI. Clinical trial design-towards better practices. J Eur Acad Dermatol Venereol 2005; 19 (Suppl.1): 40-42.
34. Gupta AK, Ryder JE. How to improve cure rates for the management of onychomycosis. Dermatol Clin 2003; 21: 499-505.
35. Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000; 38: 391-392.
36. Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology 2000; 200: 185-187.
37. Gupta AK, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol 2002; 16: 579-586.
38. Gupta AK, Lynch LE. Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. Cutis 2004; 74: 5-9.
39. Lestringant GG, Nsanze H, Nada M et al. Effectiveness of amorolfine 5% nail lacquer in the treatment of long-duration Candida onychomycosis with chronic paronychia. J Dermatol Treat 1996; 7: 89-92.
40. Di Chiacchio N, Kadunc BV, Almeida ART, Madeira CL. Nail abrasion. J Cosm Dermatol 2004; 2: 150-152.